Saturday 17 October 2026
Export ADMA’s income statement to Excel — free account
ADMA Biologics Inc
ADMA Healthcare Biotechnology
ADMA Biologics Inc’s revenue for fiscal 2025 (year ended December 2025) was $510.2 million, up 19.6% from fiscal 2024. In the quarter to June 2026, revenue grew 1.98%, EPS grew 21.4%, free cash flow grew 19.7% and total debt rose 140.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
10.68
0.05
−0.47%
Follow ADMA
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.42 | 29.90 |
Piotroski F-Score |
4 | 3 | 2 | 4 | 2 | 4 | 5 | 6 | 7 | 5 |
P/S ratio |
5.68 | 3.32 | 6.36 | 7.41 | 3.98 | 2.43 | 4.97 | 3.95 | 9.37 | 8.52 |
Altman Z-Score |
(6.43) | (1.70) | (4.05) | (1.79) | (1.51) | (0.84) | 1.29 | 2.74 | 18.78 | 19.98 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 252.94 | 36.31 | 158.03 |
Altman Z″-Score (non-manufacturers) |
(16.91) | (3.16) | (9.62) | (5.00) | (2.44) | (0.95) | (0.07) | 0.29 | 6.18 | 8.80 |
Beneish M-Score |
(2.63) | — | — | — | — | (17.73) | (2.93) | (2.52) | 0.13 | (0.17) |
P/Operating CF |
(16.75) | (5.66) | (5.75) | (11.06) | (5.21) | (5.88) | (103.78) | 57.91 | 79.60 | 121.96 |
P/B ratio |
0.00 | 1.87 | 5.46 | 8.30 | 1.90 | 1.39 | 5.04 | 7.54 | 11.45 | 9.11 |
Price to Tangible BV |
0.00 | 2.36 | 8.83 | 11.15 | 2.04 | 1.45 | 5.19 | 7.77 | 11.59 | 9.19 |
EV/Sales |
5.40 | 3.19 | 7.46 | 9.38 | 4.96 | 3.07 | 5.41 | 4.29 | 9.32 | 8.50 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 34.19 | 26.89 | 21.66 |
EV/Operating CF |
(3.15) | (1.95) | (2.02) | (3.61) | (2.05) | (2.21) | (14.00) | 125.95 | 33.50 | 86.02 |
EV/FCF |
(3.14) | (1.82) | (1.96) | (3.44) | (1.83) | (1.97) | (11.35) | 275.09 | 36.11 | 157.61 |
Quick Ratio |
1.45 | 4.98 | 2.51 | 2.15 | 3.47 | 2.62 | 2.60 | 1.58 | 2.76 | 3.54 |
Current Ratio |
1.93 | 6.60 | 4.63 | 6.12 | 7.71 | 6.87 | 6.89 | 5.16 | 5.97 | 6.71 |
Net Debt/EBITDA |
(0.19) | 0.08 | (0.33) | (1.56) | (0.70) | (1.00) | (2.23) | 2.75 | (0.15) | (0.06) |
Debt/Assets |
77.89% | 37.23% | 46.65% | 66.67% | 46.85% | 37.04% | 44.06% | 42.64% | 16.55% | 12.17% |
Debt/Equity |
(4.14) | 1.00 | 2.10 | 3.23 | 1.10 | 0.72 | 1.01 | 1.04 | 0.23 | 0.16 |
Asset Turnover |
0.45 | 0.35 | 0.17 | 0.27 | 0.25 | 0.33 | 0.49 | 0.76 | 1.04 | 0.92 |
Operating CF/Net income |
0.94 | 0.85 | 0.95 | 1.58 | 1.35 | 1.57 | 0.90 | (0.31) | 0.60 | 0.34 |
Capex/Depreciation |
(0.07) | (0.80) | (0.48) | (0.89) | (2.28) | (1.86) | (1.48) | (0.46) | (0.97) | (2.64) |
Interest Coverage |
(7.74) | (11.96) | (10.92) | (4.61) | (5.42) | (4.47) | (2.04) | 0.86 | 9.98 | 26.93 |
| 1,073.35% | (243.95%) | (218.77%) | (210.08%) | (132.38%) | (62.46%) | (44.96%) | (19.67%) | 81.65% | 35.56% | |
| (82.34%) | (66.45%) | (66.78%) | (44.71%) | (45.25%) | (29.61%) | (21.10%) | (8.33%) | 48.34% | 26.40% | |
ROIC |
0.00% | (65.63%) | (97.92%) | (30.76%) | (31.30%) | (18.96%) | (11.23%) | 6.03% | 26.58% | 25.69% |
Return on Tangible Assets |
(156.94%) | (52.49%) | (101.11%) | (46.63%) | (43.19%) | (31.25%) | (22.77%) | (10.82%) | 59.80% | 31.80% |
Average Days of Receivables |
34.85 | 62.22 | 29.92 | 43.15 | 114.44 | 128.86 | 36.73 | 38.76 | 42.79 | 113.35 |
Research and Development Expense of Revenue |
72.12% | 24.47% | 23.11% | 7.99% | 13.99% | 4.50% | 2.35% | 1.28% | 0.43% | 0.93% |
Selling, General and Administrative Expense of Revenue |
79.68% | 82.39% | 132.48% | 88.28% | 83.02% | 53.00% | 34.05% | 22.86% | 17.38% | 17.95% |
Intangible Assets out of Total Assets |
0.00 | 0.08 | 0.08 | 0.05 | 0.03 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 |
Share Based Compensation of Revenue |
11.73% | 6.86% | 13.09% | 9.03% | 6.76% | 4.31% | 3.38% | 2.40% | 3.19% | 3.93% |
Graham Net Nets |
(0.11) | (0.07) | (0.23) | (0.07) | 0.20 | 0.37 | 0.10 | 0.06 | 0.05 | 0.07 |
Graham Number |
3.66 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.32 | 5.24 |
Earnings Yield |
(32.53%) | (57.26%) | (61.09%) | (22.50%) | (45.13%) | (37.59%) | (8.79%) | (2.86%) | 4.90% | 3.34% |
Free Cash Flow Yield |
(30.31%) | (52.87%) | (59.98%) | (36.80%) | (68.30%) | (63.96%) | (9.59%) | 0.40% | 2.75% | 0.63% |
Revenue per Share |
0.88 | 0.99 | 0.38 | 0.54 | 0.49 | 0.58 | 0.78 | 1.15 | 1.83 | 2.14 |
Operating CF per Share |
(1.50) | (1.63) | (1.39) | (1.40) | (1.18) | (0.81) | (0.30) | 0.04 | 0.51 | 0.21 |
Capex per Share |
(0.01) | (0.12) | (0.05) | (0.07) | (0.15) | (0.10) | (0.07) | (0.02) | (0.04) | (0.10) |
Free Cash Flow per Share |
(1.51) | (1.74) | (1.43) | (1.47) | (1.33) | (0.90) | (0.37) | 0.02 | 0.47 | 0.12 |
Cash per Share |
1.26 | 1.88 | 0.50 | 0.49 | 0.65 | 0.37 | 0.44 | 0.23 | 0.44 | 0.37 |
Shareholders Equity per Share |
(0.37) | 1.76 | 0.44 | 0.48 | 1.02 | 1.01 | 0.77 | 0.60 | 1.50 | 2.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.37) | 1.76 | 0.44 | 0.48 | 1.02 | 1.01 | 0.77 | 0.60 | 1.50 | 2.00 |
Free Cash Flow |
(18.34) | (39.95) | (64.77) | (80.01) | (114.73) | (125.88) | (73.42) | 3.82 | 110.10 | 27.51 |
Working Capital |
10.43 | 52.90 | 34.90 | 71.79 | 133.79 | 178.35 | 231.14 | 207.21 | 275.87 | 396.97 |
Capital Expenditures |
(0.07) | (2.68) | (2.10) | (3.81) | (12.72) | (13.51) | (13.91) | (4.98) | (8.57) | (22.89) |
Net Current Asset Value |
(6.49) | (5.34) | (24.58) | (15.08) | 34.32 | 73.65 | 73.92 | 63.04 | 191.75 | 319.59 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 51.24 | 28.60 | 22.64 |
Capex to Sales |
0.01 | 0.12 | 0.12 | 0.13 | 0.30 | 0.17 | 0.09 | 0.02 | 0.02 | 0.04 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 47.11 | 28.76 | 22.70 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.50 | 0.11 | 0.15 | 0.14 | 0.13 | 0.14 | 0.16 | 0.20 | 0.16 | 0.13 |
Cash ROIC |
(62.61%) | (32.31%) | (77.12%) | (58.11%) | (47.51%) | (42.73%) | (18.73%) | 1.17% | 20.65% | 4.29% |
Accounts Receivable Turnover |
10.98 | 9.29 | 6.44 | 12.07 | 5.05 | 3.87 | 6.99 | 12.03 | 11.02 | 4.90 |
Accounts Payable Turnover |
2.73 | 6.87 | 7.14 | 5.24 | 6.05 | 6.79 | 9.26 | 11.72 | 11.53 | 10.17 |
Inventory Turnover |
1.50 | 3.31 | 2.70 | 1.10 | 0.91 | 0.77 | 0.83 | 1.01 | 1.21 | 1.15 |
Average Days of Payables |
147.17 | 74.10 | 51.04 | 84.77 | 65.95 | 56.87 | 40.64 | 33.77 | 35.67 | 37.81 |
Days of Inventory on Hand |
288.07 | 158.05 | 161.04 | 490.29 | 485.56 | 570.69 | 501.60 | 372.83 | 300.32 | 346.63 |
Average Receivables |
0.97 | 2.45 | 2.64 | 2.43 | 8.35 | 20.91 | 22.04 | 21.46 | 38.71 | 104.21 |
Average Payables |
2.33 | 4.24 | 5.91 | 7.54 | 10.12 | 11.75 | 12.83 | 14.44 | 17.94 | 21.37 |
Average Inventory |
4.23 | 8.82 | 15.62 | 35.84 | 67.30 | 103.13 | 144.00 | 168.09 | 171.57 | 188.35 |
Average Assets |
23.70 | 65.85 | 98.45 | 107.98 | 167.38 | 241.96 | 312.36 | 338.82 | 408.93 | 556.46 |
Average Common Equity |
(1.82) | 17.94 | 30.05 | 22.98 | 57.22 | 114.71 | 146.57 | 143.59 | 242.11 | 413.17 |
Columns are period end dates